|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lymphoma | |||||
| 2 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 3 | Interventions listed in this trial | ||||
| CD45 antibodies | |||||
| EBV specific T cells | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Antibodies | |||||
| 5 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 6 | Sponsors listed in this trial | ||||
| Baylor College of Medicine | |||||
| The Methodist Hospital System | |||||
| Texas Children's Hospital | |||||
| Center for Cell and Gene Therapy | |||||